Trial reportBMC pregnancy and childbirth2022
The prognostic utility of soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PIGF) biomarkers for predicting preeclampsia: a secondary analysis of data from the INSPIRE trial.
Trial report in BMC pregnancy and childbirth, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 24 citations in OpenAlex.
- Soluble fms-like tyrosine kinase-1 and placental growth factor as predictors of adverse maternal events in women with a confirmed diagnosis of preeclampsia.Pregnancy (Hoboken, N.J.) · 2026Article
- Evaluation of analytical performance of the Revvity sFlt-1 and PlGF methods for the assessment of preeclampsia.British journal of biomedical science · 2026Article
- The Role of Angiogenetic Factors in Preeclampsia.International journal of molecular sciences · 2025Review
- Characteristics of lipid metabolism dysfunction in hypertensive disorders of pregnancy.BMC pregnancy and childbirth · 2025Article
- Endoplasmic reticulum stress: an emerging therapeutic target for preeclampsia†.Biology of reproduction · 2025Review
- Correlation of supplement folic acid based on MTHFR and MTRR gene polymorphisms with preeclampsia in Chinese population: an retrospective cohort study.Frontiers in nutrition · 2025Article
- Role of circular RNAs in preeclampsia (Review).Experimental and therapeutic medicine · 2024Review
- Epigenetic biomarker for preeclampsia-associated preterm birth and potential preventative medicine.Environmental epigenetics · 2024Article
- Predictive value of the sFlt‑1/PlGF ratio in women with suspected preeclampsia: An update (Review).International journal of molecular medicine · 2023Article
- Utility of sFtl-1 and Placental Growth Factor Ratio for Adequate Preeclampsia Management.Healthcare (Basel, Switzerland) · 2023Article
- Leveraging the placenta to advance neonatal care.Frontiers in pediatrics · 2023Review
- Exploring Preeclampsia: A Comprehensive Overview.Discoveries (Craiova, Romania)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo compare the prognostic performance of biomarkers soluble fms-like tyrosine kinase-1 (sFlt-1), Placental Growth Factor (PIGF), and sFlt-1/PIGF ratio as continuous values or as a binary cut-off of 38 for predicting preeclampsia (PE) within 7 days.
designSecondary analysis of a randomised clinical trial.
settingOxford University Hospitals, Oxford, United Kingdom (UK). POPULATION: Pregnant women between 24 MAIN OUTCOME: Onset of preeclampsia within 7 days of the initial biomarker test.
methodsLogistic regression model for onset of preeclampsia using: (i) sFlt-1 (ii) PIGF, (iii) sFlt-1/PIGF ratio (continuous), and (iv) sFlt-1/PIGF ratio as a cut-off above or below 38.
resultsOf the total 370 women, 42 (11.3%) developed PE within 7 days of screening. Models with sFlt-1 and sFlt-1/PIGF ratio (continuous) had greater overall performance than models with PIGF or with sFlt-1/PIGF ratio as a cut-off at 38 (R
conclusionModels using continuous values of sFlt-1 only or sFlt-1/PIGF ratio had better predictive performance compared to a PIGF only or the model with sFlt-1/PIGF ratio as a cut-off at 38. Further studies based on a larger sample size are warranted to substantiate this finding.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.